Sell-off talk again hits Sandoz

Posted 27 October 2021 PM

With generics subsidiary Sandoz dragging on the performance of Novartis the pharmaceutical giant is again looking at shedding the division, undertaking a "strategic review" into which options maximise value.

In its third quarter results Novartis reported net sales growing five per cent year-on-year in constant currency. Its Innovative Medicines division grew seven per cent, but the generics division Sandoz declined two per cent due to ongoing pricing pressures.

To see the whole article, please login